| HOME >> MEDICINE >> TECHNOLOGY |
RELATED BCC STUDIES 2
ANALYST CREDENTIALS 3
BCC ON-LINE SERVICES 3
DISCLAIMER 3
CHAPTER TWO: SUMMARY 4
SUMMARY 4
SUMMARY (CONTINUED) 5
SUMMARY TABLE GLOBAL MARKET FOR PULMONARY DRUG
DELIVERY TECHNOLOGIES, THROUGH 2016 ($ MILLIONS) 6
SUMMARY FIGURE GLOBAL MARKET FOR PULMONARY DRUG
DELIVERY TECHNOLOGIES, 2010–2016 ($ MILLIONS) 6
CHAPTER THREE: OVERVIEW 7
TECHNOLOGY TRENDS 7
PULMONARY DRUG DELIVERY 8
PULMONARY CONDITIONS AND THERAPIES 8
RESPIRATORY SYSTEM 9
Respiratory System (Continued) 10
Lung 11
Particle Size, Toxicity and Drug Deposition 11
SYSTEMIC AND LOCAL THERAPY 12
Pulmonary Drug Delivery-Devices 13
Device Characteristics 13
Device Characteristics (Continued) 14
Device Characteristics (Continued) 15
Device Characteristics (Continued) 16
Device Characteristics (Continued) 17
Device Characteristics (Continued) 18
Pulmonary Drug Delivery – the Future 19
Inhaler Devices 19
TABLE 1 INHALER DEVICES AND CHARACTERISTICS 19
TABLE 2 DOSAGE FORMS-INHALERS 20
Available Products 20
TABLE 3 METERED DOSE INHALERS 20
Available Products (Continued) 21
TABLE 4 DRY POWDER INHALERS 22
INHALER-DRUG PROFILES 22
Aerosol Aztreonam (Cayston) 22
Dulera (mometasone furoate/formoterol fumarate
dihydrate) 23
Amikacin 24
SYSTEMIC PULMONARY DELIVERY 25
Development of Exubera 25
Lung Cancer Concerns 26
Aerogen and Dance Pharmaceuticals 27
Safety Concerns 27
Future 27
Insulin -Exubera 28
MannKind's –Afrezza 29
Summary 30
Key Players 30
Pulmonary Drug Delivery-In a New Light 30
ASTHMA AND COPD – MAJOR RESPIRATORY DISEASE
CONDITIONS 31
Asthma: Primary Respiratory Syndrome 31
Asthma
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |